Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 9/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6033353 | 0.85 | TGM2 (0.71) | TGM2NPSR1SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6037615 | 0.84 | TGM2 (1.00) | TGM2 | |
| SCHEMBL6033420 | 0.84 | TGM2 (0.70) | TGM2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6034215 | 0.80 | TP53 (0.72) | TGM2NPSR1SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6034168 | 0.80 | TGM2 (0.72) | TGM2TSHR | |
| SCHEMBL6037627 | 0.79 | TGM2 (0.76) | TGM2MEN1KMT2ATP53 | |
| SCHEMBL6034184 | 0.79 | TGM2 (0.73) | TGM2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6034163 | 0.78 | TGM2 (0.72) | TGM2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6033346 | 0.75 | TGM2 (0.65) | TGM2NPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL6034870 | 0.74 | TGM2 (0.60) | TGM2NPSR1SMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183759-A1 | Tissue transglutaminase inhibitors | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE | 2006-08-17 | — | — | US | disclosed |
| WO-2006060702-A1 | SUBSTITUED 3,4-DIHYDROTHIENO [2,3-D] PYRMIDINES AS TISSUE TRANSGLUTAMINASE INHIBITORS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183759-A1 | Tissue transglutaminase inhibitors | TGM2, HNMT, TPMT | TGM2 1/4885NPSR1 4134/4885SMN1; SMN2 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.